November 25, 2020

Biosimilar infliximab administration for the management of acute graft-versus-host disease

Acute graft-versus-host disease (aGVHD) is a major immune-mediated complication of allogeneic hematopoietic stem cell transplant (HSCT). Despite prophylactic immunosuppression, the incidence of grades II-IV aGVHD …

Read moreBiosimilar infliximab administration for the management of acute graft-versus-host disease